{"id":"W3126084116","doi":"10.1200/jco.2021.39.3_suppl.411","title":"Predictive value of plasma tumor mutation burden (TMB) in the CCTG PA.7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs. GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen's University; Genome British Columbia; Sunnybrook Health Science Centre; Cancer Care Ontario; Université de Montréal; Centre Hospitalier Universitaire de Sherbrooke; BC Cancer Agency; Hôpital Notre-Dame; Centre hospitalier universitaire de Québec; Vancouver General Hospital; University of Calgary; Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network; Ottawa Hospital; McGill University; Moncton Hospital","funders":"","keywords":"Medicine; Internal medicine; Gemcitabine; Clinical endpoint; Microsatellite instability; Gastroenterology; Oncology; Urology; Randomized controlled trial; Cancer; Allele; Gene","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002031527,0.0006382558,0.001331099,0.0002363191,0.0002016905,0.0007540855,0.000470753,0.001140132,0.002565507],"category_scores_gemma":[0.003348809,0.0003131943,0.001152202,0.0003000614,0.0004446013,0.0006609226,0.0002840761,0.002320099,0.0003202943],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006933421,"about_ca_system_score_gemma":0.0009556031,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009927952,"about_ca_topic_score_gemma":0.002321557,"domain_scores_codex":[0.9991533,0.0005764553,0.0000366393,0.0001043225,0.00006036785,0.00006892476],"domain_scores_gemma":[0.9978278,0.001055882,0.0004782327,0.0001036908,0.0001072519,0.0004271357],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9474211,0.001987331,0.01465718,0.0003557345,0.001361003,0.00005371005,0.00006090344,0.001741649,0.003540834,0.000143896,0.002614085,0.0260624],"study_design_scores_gemma":[0.6317564,0.2379046,0.09882617,0.0002254416,0.006223285,0.0004967191,0.00009685918,0.01710826,0.002576869,0.0008393363,0.003871337,0.00007474917],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957485,0.001739779,0.0001604106,0.0003910692,0.00008048472,0.0002015824,0.0004817085,0.00002702828,0.001169611],"genre_scores_gemma":[0.9970647,0.0004077669,0.0003080168,0.0002283573,0.0001331119,0.0002478348,0.001010189,0.00001154666,0.0005886432],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002565507,"threshold_uncertainty_score":0.01074386,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.106042169096717,"score_gpt":0.4437832471874044,"score_spread":0.3377410780906873,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}